FDA staff recommends limited use of Daiichi's blood thinner

(Reuters) - U.S. Food and Drug Administration staff reviewers recommended approval of a 60 mg dose of Daiichi Sankyo Co's blood thinner for certain atrial fibrillation patients, but suggested limiting its use in those with abnormal kidney function. The drug, edoxaban, is a once-daily anticoagulant that inhibits Factor Xa, a protein playing a central role in blood-clotting. Edoxaban is being considered for use in some patients with atrial fibrillation, characterized by a rapid and irregular heartbeat that can cause strokes. "Although the ... ...

via Health News Headlines - Yahoo News http://ift.tt/1tFdOAR